Abstract
Background Patients on antithrombotic drugs are at risk of thrombosis; when prescribed these medications they develop a risk of haemorrhage. To our knowledge, there is no published global consensus on the management of these patients and only expert panels guidelines exist. Objectives The aims of this study were to (1) compare the clinical guidelines issued by the French Society of Oral Surgery (SFCO) and the clinical guidelines issued by the British Association of Oral Surgery (BAOS), and (2) to summarize the guidelines recommendations. Methods This article is a descriptive comparative review based on published clinical guidelines issued by the French Society of Oral Surgery (SFCO) in July 2015 and the clinical guidelines issued by the British Association of Oral Surgery (BAOS) in March 2022. Results The decisions of the two bodies overlap in that the discontinuation of antithrombotic drugs is considered a last resort decision. However, distinctions arise from the approach to determining bleeding risk, which extends to differences in management strategy and decision making. Conclusion Many of the most recent SFCO and BAOS guidelines are based on conditional recommendations with a seven-year gap. For optimal management, practitioners need to consider these parameters while keeping abreast of the latest studies.
Recommended Citation
Lahlou, Meryem; Naji, Yousef; Nabih, Ossama; and Yahya, Ihsane Ben
(2023)
"Management of patients treated with antithrombotic drugs in dentistry: Comparison of SFCO and BAOS recommendations,"
Health Sciences: Vol. 4
:
Iss.
1
, Article 10.
Available at:
https://doi.org/10.56264/2658-865X.1089
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Included in
Biomedical Engineering and Bioengineering Commons, Dentistry Commons, Nursing Commons, Pharmacy and Pharmaceutical Sciences Commons, Public Health Commons
